Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

Newswise—November 10, 2022— For patients with solitary prostate cancer metastasesAn approach called metastasis-directed therapy (MDT), a targeted treatment that uses surgery or radiation therapy, without androgen deprivation therapy (ADT), can delay the time to progression of the disease. cancer, reports a study in The Journal of Urology®, an official journal of the American Urological Association (AUA). The magazine is published in the Lippincott Portfolio by Wolters Kluwer.

“Metastasis-directed therapy has been a controversial approach to the management of solitary metastatic recurrences of prostate cancer,” says senior author Jack R. Andrews, MD, Mayo Clinic Arizona, Phoenix. “Our study is the first to show the benefits of both surgical MDT and radiotherapy without ADT in this group of patients, which could delay the need for systemic treatment.”

MDT as a possible alternative target area for cancer spread

Metastasis-directed therapy has emerged as a possible alternative for men with “oligo-recurrent” prostate cancer, a disease state with a limited number of metastatic lesions after initial treatment. In the MDT approach, surgery or radiation therapy (stereotactic body radiation therapy, or SBRT) is used to specifically target the area of ​​cancer spread.

That’s in contrast to ADT, systemic therapy to block testosterone and other male sex hormones, which promote prostate cancer growth. Androgen deprivation therapy with or without other systemic therapy is the standard treatment for metastatic prostate cancer, but it has numerous adverse effects that can decrease quality of life, including sexual dysfunction, bone thinning, and weight loss. muscle strength, among others. If MDT is effective in controlling limited recurrences, it may prevent or delay the need for ADT.

Dr. Andrews and colleagues evaluated their center’s experience with MDT, without ADT, in 124 patients with oligorecurrent prostate cancer between 2008 and 2018. Treatment consisted of surgery in 67 patients, most with lymph node metastases; and radiation in 57 patients, most with bone metastases. In both groups, the mean follow-up time was about four and a half years.

Promising results with MDT for oligorecurrent prostate cancer

Both forms of MDT were effective in terms of biochemical recurrence, reflected by the reduction in the level of prostate-specific antigen (PSA). After surgery, the PSA level decreased by approximately half in 80.5% of patients after MDT. Most patients eventually required ADT or other systemic therapy for progressive cancer, median time 18.5 months. However, at three years of follow-up, 29% of patients were alive and free of cancer progression.

In the radiation therapy group, 40.3% of patients had a halved reduction in PSA level. The median time to systemic therapy was 17%, while the three-year progression-free survival was 17%. The researchers emphasize that their study was not designed to compare the results of surgery and radiation, since the two types of MDT were used in patients with different types of cancer metastases (lymph node versus bone).

“The role of MDT in prostate cancer remains highly controversial, with insufficient evidence to make recommendations in current guidelines,” write Dr. Andrews and coauthors. They point to some key limitations of their study, including selection bias related to the fact that patients who opted for MDT were likely part of a “healthier, more robust” group seeking a more aggressive treatment option.

“These results suggest that MDT without ADT may delay the initiation of systemic therapy” in men with oligorecurrent prostate cancer, Dr. Andrews and colleagues conclude. They call for further studies to determine which patients with solitary metastases may benefit most from MDT.

Read [Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer]

DOI: 10.1097/JU.0000000000002898

###

On The Journal of Urology®

The Official Gazette of the American Urological Association (AUA), and the most widely read and cited journal in the field, The Journal of Urology® provides robust coverage of the clinically relevant content needed to stay ahead of the dynamic field of urology. This premier journal features research studies on critical areas of research and practice, survey articles providing brief editorial commentary on the best and most important urology literature from around the world, and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the broad spectrum of urology, including pediatric urology, urologic cancers, kidney transplantation, male infertility, urinary tract stones, female urology, and neurourology.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, with more than 23,000 members worldwide. The AUA is a premier urological association providing invaluable support to the urological community in its mission to advance the highest standards of urological care through education, research, and health care policymaking. To learn more about the AUA visit: www.auanet.org

About Wolters Kluwer

Wolters Kluwer (WKL) is a world leader in professional information, software solutions and services for doctors, nurses, accountants, lawyers and the tax, finance, audit, risk, compliance and regulatory sectors. We help our clients make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported annual revenue of €4.8 billion in 2021. The group serves customers in more than 180 countries, maintains operations in more than 40 countries, and employs approximately 19,800 people worldwide. The company is based in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective healthcare decisions and outcomes. We support clinical efficacy, learning and research, clinical surveillance and compliance, and data solutions. To learn more about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKShealth.

For more information visit www.wolterskluwer.esfollow us Twitter, Facebook, LinkedInY Youtube.

Leave a Comment